Latest "Mifepristone Cushing Syndrome" News Stories

09:09 EDT 27th March 2015 | BioPortfolio

Here are the most relevant search results for "Mifepristone Cushing Syndrome" found in our extensive news archives from over 250 global news sources.

More Information about Mifepristone Cushing Syndrome on BioPortfolio

In addition to our news stories we have dozens of PubMed Articles about Mifepristone Cushing Syndrome for you to read. Along with our medical data and news we also list Mifepristone Cushing Syndrome Clinical Trials, which are updated daily. BioPortfolio also has a large database of Mifepristone Cushing Syndrome Companies for you to search.

Showing "Mifepristone Cushing Syndrome" News Articles 1–25 of 1,900+

Extremely Relevant

Rapid expansion forecast for global Cushing’s syndrome drug market

The global Cushing’s syndrome (CS) treatment market will expand rapidly in value from around $179 million in 2013 to $499 million by 2018, representing an impressive compound annual growth rate (CAGR) of 22.74%, according to a new study.

Relevant

Speculative Thoughts Corcept Therapeutics (CORT)

In recent posting, we have characterized Corcept as a surprising “comeback’ story. The stock is trading near levels seen before last May’s disappointing Phase III trial results for psychotic depression.Corcept recently gave guidance of $47M to $53M in 2015 sales for Korlym (AKA mifepristone) to treat Cushing’s syndrome.

Thoughts on Corcept Therapeutics' (CORT) Update

On Thursday, January 29, 2015, Corcept Therapeutics reported Q4 and FY 2014 revenue and held a conference call. In sum, we were treated to a positive outlook, more than we had previously anticipated.     Corcept continues to report increasing sales of Korlym     Korlym sales are projected to roughly double for 2015

EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023

Recently added to the BioPortfolio report store, EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023 is a new report from GlobalData published on 2014-10-26. This 58-page report is available in PDF from $3995. EpiCast Report: Cushing’s Syndrome - Epidemiology Forecast to 2023 Summary Cushing’s syndrome (CS) is a rare disorder caused by prolonged exposure to excess amounts of...

Corcept Therapeutics Announces Nine Poster Presentations on Mifepristone for the Treatment of Cushing's Syndrome at the 97th Annual Endocrine Society Meeting

MENLO PARK, CA -- (Marketwired) -- 03/05/15 -- Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company engaged in the discovery, development and commercialization of drugs for the treatment of severe metabolic, oncologic and psychiatric disorders, today announced that a variety of posters about Korlym® (mifepristone) will be presented at the 97th annual Endocrine Society Meeti...

A C-terminal HSP90 inhibitor restores glucocorticoid sensitivity and relieves a mouse allograft model of Cushing disease

Inhibition of Hsp90 as its C-terminus allows for the mature folding of GR and its full activity, thus ameliorating Cushing symptoms in a mouse model.

Genetic defect triggers endless recycling

Benign tumors in the pituitary gland are responsible when adrenal gland cells secrete the stress hormone cortisol unchecked. An international team of scientists has now succeeded in mapping out in detail the molecular processes that lie behind this. ...

Corcept Therapeutics (CORT) Releases Q4 2014 Financials and Update

On March 4, 2015, Corcept Therapeutics (CORT) released its quarterly financial results for Q4 2014 and provided a clinical update. In the earlier release, Corcept provided limited data and sales guidance for 2015.The effect of increasing sales on the financial metrics is immediately apparent.  While net sales was only $26.6M for 2014, it made a significant difference. The net loss was $3.9M f...

Cortendo AB: COR-003 Phase 3 Study Protocol to Be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Regulatory News: Cortendo AB  [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing’s syndrome at ENDO 2015: The Endocrine Society’s 97th Annual Meeting &...

PIPE brings in SEK221mm for Cortendo

Cortendo AB (developing therapies for orphan endocrine disorders) raised SEK221mm ($26.2mm) through the placement of 52.3mm shares at SEK4.22 (a 48% discount) to RA Capital Management, New Enterprise Associates, Broadfin Capital, and HealthCap. Funds...

COR-003 Phase 3 Study Protocol to be Presented at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo

Cortendo AB [ticker: CORT on NOTC-A], a global biopharmaceutical company initially focused on orphan endocrine disorders, today announced that it will present the study protocol of its global Phase 3 study of COR-003 in patients with endogenous Cushing’s syndrome at ENDO 2015: The Endocrine Society’s 97th Annual Meeting & Expo March 5-8 in San Dieg...

PIPE grosses SEK81.5mm for Cortendo AB

Cortendo AB (orphan endocrine disorders) grossed SEK81.5mm ($11.2mm) through the private sale of 19.3mm common shares at SEK4.22 (an 11% discount) to HealthCap, the Third Swedish National Pension Fund, Storebrand, and Arctic Fund Management. Cortendo...

Genetics of adrenal diseases in 2014: Genetics improves understanding of adrenocortical tumours

2014 has seen advances in our understanding of benign and malignant tumours of the adrenal cortex, particularly in Cushing syndrome. Modern genetics has generated a flurry of data. The challenge is to give sense to them; however, the difficulties of ...

Gilberts Syndrome

Gilbert’s syndrome is a common, harmless condition that can run in families. People with this syndrome sometimes get jaundice when they are under stress, take certain medicines, or have an infection. Women with Gilbert’s syndrome might get jaundi...

Celebrating the Biomedical Achievements on World Down Syndrome Day

Guest Post by Sara Hart Weir, MS, President, National Down Syndrome Society On March 21, we celebrate the 10th Annual World Down Syndrome Day.  It was established and eventually recognized by the United Nations as a means to raise awareness and mo...

New Tool for Down Syndrome Research

Researchers, clinicians, and other professionals with an interest in Down syndrome can now access deidentified data from DS-Connect: The Down Syndrome Registry, where people in the Down syndrome community voluntarily and securely store personal healt...

High prevalence of ophthalmic disorders in Down's syndrome

Jensen and Bulova’s otherwise excellent review of the care of adults with Down’s syndrome did not mention the ocular manifestations of Down’s syndrome, which are common and can seriously reduce...

Genetics: New mutations in Cushing disease identified

Milk thistle extract helps fight brain tumors

Provided by Marcelo Paez-Pereda, Max-Planck-Gesellschaft Cushing's Syndrome, is caused by a tumor in the pituitary gland in the brain. The tumor secretes increased amounts of the stress hormone adrenocorticotropin (ACTH) followed by cortisol release from the adrenal glands leading to rapid weight gain, elevated blood pressure and muscular weakness. Patients are prone to osteoporosis, infections a...

Medical News Today: Down syndrome: what is the current focus of research?

In our follow-up to yesterday's Down Syndrome Awareness Month spotlight feature, we talk to some of the leading experts in Down syndrome research.

Resting-State Functional Connectivity in Patients with Long-Term Remission of Cushing’s Disease

Down Syndrome: What Is the Current Focus of Research?

(Medical News Today) – Yesterday, as part of Down Syndrome Awareness Month, we looked at some of the controversial issues and popular perceptions surrounding pregnancy and Down syndrome. Now, in a follow-up feature, we speak to scientists and o...

TransCanada Presents Check to CRH Foundation

TransCanada has joined the many donors committed to providing financial assistance to many patients requiring breast cancer treatment. SOURCE: TransCanada DESCRIPTION:TransCanada has joined the many donors committed to providing financial assistance to many patients requiring breast cancer treatment. Tracy Walker, Manager of the Cimarron Area, returned to Cushing after being gone for seven years ...

Managing the care of adults with Down's syndrome

Summary pointsPeople with Down’s syndrome have experienced a dramatic increase in life expectancy, which is now in their mid-50sThe approach to primary care for adults with Down’s syndrome is similar...

IBS is no BS

Millions of people are diagnosed with irritable bowel syndrome (IBS) every year making it one of the most common gastrointestinal (GI) conditions. Despite its prevalence, there remain many misconceptions about IBS among both patients and doctors. Here we review some basic concepts in hopes of demystifying this nebulous syndrome. What is IBS? Irritable bowel syndrome […]


Search BioPortfolio:
Loading
Advertisement
Advertisement

News Quicklinks